This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next-generation HMA and …

May 6, 2021 · This review provides insights into the mode of action of HMA, mechanisms of resistance to this treatment, and strategies to overcome HMA resistance including next …

Venetoclax and hypomethylating agent (HMA) combination therapy is FDA-approved for elderly or unfit acute myeloid leukemia (AML) patients unable to withstand intensive chemotherapy. The …

Nov 5, 2024 · Patients with some MR mutations have been shown to benefit from venetoclax plus hypomethylating agents (VEN+HMA) regimen. VEN+HMA and intensive chemotherapy have …

Oct 18, 2019 · Venetoclax is an oral BCL-2 protein inhibitor recently approved by the United States Food and Drug Administration (FDA) for use in combination with a hypomethylating …

Hypomethylating agents (HMA) have played a pivotal role for treating myelodysplastic syndromes (MDS) over the past decade, inducing sustained hematological responses and delaying …

Nov 5, 2020 · VEN is approved conditionally in the US in combination with HMA (azacitidine or decitabine) or low-dose cytarabine in newly-diagnosed AML patients (pts) ineligible for …

2023年3月3日，急性髓系白血病（aml）nccn指南更新至2023.v1，此次更新的主要内容为aml诱导治疗策略的决定因素发生变化；维持治疗方案新增hma、flt3抑制剂等药物。

One of the most promising developments in therapy for acute myeloid leukemia (AML) in recent years has been the combination of hypomethylating agents (HMA, either decitabine or 5 …

Dec 8, 2023 · Peripheral blood flow cytometry demonstrates acute myeloid leukemia (AML). A repeat ejection fraction is 55%. Imaging demonstrates nodularity in the lung parenchyma and …